Compare Mesoblast Limited (MESO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Phillips 66 — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Phillips 66 trades at $210.39 (market cap $83.72B). The key difference: Phillips 66 is far larger — about 38.6× Mesoblast Limited's market cap, and Phillips 66 pays a 2.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PSX | |
|---|---|---|
Market Cap | $2.17B | $83.72B |
Sector | Technology | Energy |
52-Week High | $20.96 | $208.80 |
52-Week Low | $12.88 | $118.37 |
Enterprise Value | $2.17B | $105.69B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
PSX trades at $209.47, up 1.26% on the day, with strong technical momentum and bullish moving average signals. The stock benefits from elevated refining margins and has beaten earnings expectations in three consecutive quarters. Recent news highlights its advantage from tight fuel markets and Middle East supply dynamics, while the company maintains a solid dividend payout of $1.27 per share.
Outlook remains positive with 57% analyst buy ratings and a consensus price target of $201.50, though current price exceeds this. Risks include volatile oil prices and declining revenue trends from $170B in 2022 to $132.4B in 2025. Institutional sentiment is supported by efficient refining operations and strategic positioning in current energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
